Inactive Instrument

Protalex, Inc.

Equities

PRTX

US7436422098

Biotechnology & Medical Research

Protalex, Inc. Auditor Raises 'Going Concern' Doubt

July 30, 2015

Protalex, Inc. filed its S-1 on Jul 31, 2015 for the period ending May 31, 2015. In this report its auditor, Liggett, Vogt & Webb P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Protalex, Inc.

Protalex, Inc. Announces Management Resignations	30/11/18	CI
Protalex Plans To Raise Funds	12/10/18	CI
Protalex, Inc. Announces Data Highlighting Results from European Phase 1b of PRTX-100 in Patients with Immune Thrombocytopenia	15/06/18	CI
Protalex, Inc. Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in Mouse Model of Myasthenia Gravis	12/06/18	CI
Protalex, Inc. Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia	09/04/18	CI
Protalex, Inc. announced that it has received $1.43 million in funding	27/02/18	CI
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia	18/01/18	CI
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP	13/11/17	CI
Protalex, Inc. Announces Preclinical Data of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia	26/10/17	CI
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP	29/08/17	CI
Protalex, Inc. Announces Completion of Escalating the U.S. Phase 1/2 Study of PRTX-100 in Adults	01/08/17	CI
Protalex, Inc. Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia	21/02/17	CI
Protalex, Inc. Enters Amendment to Credit Facility	07/07/16	CI
Protalex Inc. Receives Positive Interim Review from Independent Safety Monitoring Committee in its European Phase 1B Study of PRTX-100 to Treat Immune Thrombocytopenia	02/05/16	CI
Protalex Announces Preliminary Findings from Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients	25/04/16	CI
Protalex Announces Interim Review of its U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia	29/02/16	CI
Protalex, Inc. Announces First Patient Dosed in European Phase Ib Study of PRTX-100 for Immune Thrombocytopenia	07/01/16	CI
Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France	05/10/15	CI
Protalex, Inc. to Initiate Enrollment of U.S. Phase I/II Trial of PRTX-100 to Treat Immune Thrombocytopenia	03/09/15	CI
Protalex, Inc. Auditor Raises 'Going Concern' Doubt	30/07/15	CI
Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of Prtx-100 in Active Rheumatoid Arthritis Patients	16/04/15	CI
Protalex, Inc. Initiates Enrollment of Phase I/Ii Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients	12/03/15	CI
Protalex Inc. Announces Data from Phase 1b Trial of PRTX 100 in Patients with Active Rheumatoid Arthritis	18/11/14	CI
Protalex Inc. Enters New Credit Facility Agreement with Niobe Ventures, LLC	07/11/14	CI
Protalex Announces Results from Cohorts 1-4	15/05/14	CI

Chart Protalex, Inc.

Duration

Period

More charts

Company Profile

Protalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs